IPI-145
Sponsors
SecuraBio, SCRI Development Innovations, LLC, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute
Conditions
Chronic Lymphocytic LeukemiaHealthyHealthy VolunteersHepatic ImpairmentLeukemiaLymphomaNon-Hodgkin LymphomaRheumatoid Arthritis
Phase 1
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study
CompletedNCT01549106
Start: 2011-08-31End: 2012-02-29Updated: 2021-03-17
IPI-145 ADME and Absolute Bioavailability Study
CompletedNCT01836861
Start: 2013-03-31End: 2013-05-31Updated: 2021-03-17
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies
CompletedNCT01871675
Start: 2013-05-31End: 2016-06-30Updated: 2016-07-11
Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam
CompletedNCT01925911
Start: 2013-08-31End: 2013-10-31Updated: 2021-03-17
Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145
CompletedNCT01947777
Start: 2013-10-31End: 2013-12-31Updated: 2021-03-17
Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects
CompletedNCT02095587
Start: 2014-03-31End: 2014-10-31Updated: 2021-03-17
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Active, not recruitingNCT02158091
Start: 2014-06-27End: 2026-07-01Updated: 2026-02-13
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
CompletedNCT02307461
Start: 2014-11-30End: 2015-09-30Updated: 2021-03-17
Phase 2
A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone
CompletedNCT01851707
Start: 2013-04-30End: 2015-02-28Updated: 2021-03-17
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
WithdrawnNCT02028039
Start: 2013-12-31Updated: 2014-01-06